Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism

Journal of Toxicological Sciences

Volumn 25, Issue 5, 2000, Pages 423-431

  Watanabe, T ^a   Furukawa, T ^a   Sharyo, S ^a   Ohashi, Y ^a   Yasuda, M ^a   Takaoka, M ^a   Manabe, S ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Genetic polymorphism; Gunn rat; Hyperbilirubinemia; Liver dysfunction; Toxicokinetics; Troglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME POLYMORPHISM; FEMALE; GENETIC POLYMORPHISM; HYPERBILIRUBINEMIA; LIVER; LIVER DYSFUNCTION; MALE; NONHUMAN; RAT; RAT STRAIN; TOXICOKINETICS;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0034525339     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.25.5_423     Document Type: Article

References (37)

1. Properties of sufficiency and statistical tests
2. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man
3. Deficiency in bilirubin UDP-glucuronyl transferase as a genetic determinant of acetaminophen toxicity
4. Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency
5. A multiple comparisons procedure for comparing several treatments with a control
6. New tables for multiple comparisons with a control
7. Hereditary acholuric jaundice in a new mutant strain of rats
8. Mutagenicity studies of CS-045 in Bacteria, in mammalian tissue culture cells and in mice
9. Troglitazone (CS-045), A new antidiabetic drug
10. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
11. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
12. Molecular basis of multiple UDP-glucuronosyltransferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat)
13. The 3-methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a-1 frameshift mutation
14. Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data
15. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
16. Troglitazone
17. The acute toxicity studies of CS-045 in mice, rats and Cynomolgus monkeys
18. Extension of multiple range tests to group means with unequal number of replications
19. Use of ranks in one-criterion variance analysis
20. Liver dysfunction associated with troglitazone (Noscal®)
21. Subacute toxicity study on CS-045 in rats treated orally for 90 days and following 28 day withdrawal experiment
22. Chronic toxicity study on CS-045 in rats treated orally for 1 year
23. CS-045 toxicity to Cynomolgus monkeys by repeated oral administration for 52 weeks
24. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes
25. Troglitazone. A review of its use in the management of type 2 diabetes mellitus
26. Molecular basis for the lack of bilirubin-specific and 3-methylcholanthrene-inducible UDP-glucuronosyltransferase activities in Gunn rats. The two isoforms are encoded by distinct mRNA species that share an identical single base deletion
27. Isolation of multiple normal and functionally defective forms of uridine diphosphate-glucuronosyltransferase from inbred Gunn rats
28. Genetic defect of the hyperbilirubinemic Gunn rat, a model for Crigler-Najjar syndrome type I
29. Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers
30. Antigenicity studies on CS-045 in Guinea Pigs and mice
31. Ninety-day oral subacute toxicity study of CS-045 in Cynomolgus monkeys
32. Reproductive and developmental toxicity study on CS-045 administered during the period of fetal organogenesis in rabbits
33. Reproductive and developmental toxicity study on CS-045 administered during the period of fetal organogenesis in rats
34. Comparing individual means in the analysis of variance
35. Was it not possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies?
36. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 3C8 and P-450 3A4 in human liver microsomes